S. Bjorck, B. Palaszewski, L. Friberg, and L. Bergfeldt, Atrial Fibrillation, Stroke Risk, and Warfarin Therapy Revisited: A Population-Based Study, Stroke, vol.44, issue.11, pp.3103-3111, 2013.

M. Haim, M. Hoshen, O. Reges, Y. Rabi, R. Balicer et al., Prospective National Study of the Prevalence, Incidence, Management and Outcome of a Large Contemporary Cohort of Patients With Incident Non-Valvular Atrial Fibrillation, J Am Heart Assoc. 21 janv, vol.4, issue.1, pp.1486-001486, 2015.

L. Dm, Lifetime Risk for Development of Atrial Fibrillation: The Framingham Heart Study, Circulation. 23 août, vol.110, issue.9, pp.1042-1048, 2004.

J. Heeringa and . Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study, Eur Heart J. 8 août, vol.27, issue.8, pp.949-53, 2005.

S. S. Chugh, R. Havmoeller, K. Narayanan, D. Singh, M. Rienstra et al., Worldwide Epidemiology of Atrial Fibrillation: A Global Burden of Disease, Study. Circulation. 25 févr, vol.129, issue.8, pp.837-884, 2010.

M. Zoni-berisso, F. Lercari, T. Carazza, and S. Domenicucci, Epidemiology of atrial fibrillation: European perspective, Clin Epidemiol. juin, p.213, 2014.

D. D. Mcmanus, M. Rienstra, and E. J. Benjamin, An Update on the Prognosis of Patients With Atrial Fibrillation. Circulation. 4 sept, vol.126, pp.143-149, 2012.

J. Ball, M. J. Carrington, J. Mcmurray, and S. Stewart, Atrial fibrillation: Profile and burden of an evolving epidemic in the 21st century, Int J Cardiol. sept, vol.167, issue.5, pp.1807-1831, 2013.

W. Kannel, P. Wolf, E. Benjamin, and D. Levy, Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates 11Reprints are not available, Am J Cardiol. oct, vol.82, issue.7, pp.2-9, 1998.

T. N. Nguyen, S. N. Hilmer, and R. G. Cumming, Review of epidemiology and management of atrial fibrillation in developing countries, Int J Cardiol. sept, vol.167, issue.6, pp.2412-2432, 2013.

J. Oldgren, J. S. Healey, M. Ezekowitz, P. Commerford, A. Avezum et al., Variations in Cause and Management of Atrial Fibrillation in a Prospective Registry of 15 400 Emergency Department Patients in 46 Countries: The RE-LY Atrial Fibrillation Registry, Circulation. 15 avr, vol.129, issue.15, pp.1568-76, 2014.

S. Colilla, A. Crow, W. Petkun, D. E. Singer, T. Simon et al., Estimates of Current and Future Incidence and Prevalence of Atrial Fibrillation in the U.S. Adult Population, Am J Cardiol. oct, vol.112, issue.8, pp.1142-1149, 2013.

B. P. Krijthe, A. Kunst, E. J. Benjamin, G. Lip, O. H. Franco et al., Projections on the number of individuals with atrial fibrillation in the European Union, Eur Heart J. 1 sept, vol.34, issue.35, pp.2746-51, 2000.

T. J. Wang, Temporal Relations of Atrial Fibrillation and Congestive Heart Failure and Their Joint Influence on Mortality: The Framingham Heart Study, Circulation. 17 juin, vol.107, issue.23, pp.2920-2925, 2003.

A. Kishore, A. Vail, A. Majid, J. Dawson, K. R. Lees et al., Detection of Atrial Fibrillation After Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis, Stroke. 1 févr, vol.45, issue.2, pp.520-526, 2014.

T. Sanna, H. Diener, R. S. Passman, D. Lazzaro, V. Bernstein et al., Cryptogenic Stroke and Underlying Atrial Fibrillation, N Engl J Med. 26 juin, vol.370, issue.26, pp.2478-86, 2014.

R. B. Schnabel, X. Yin, P. Gona, M. G. Larson, A. S. Beiser et al., 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study, The Lancet. juill, vol.386, issue.9989, pp.154-62, 2015.

T. Andersson, A. Magnuson, I. Bryngelsson, O. Frøbert, K. M. Henriksson et al., Allcause mortality in 272 186 patients hospitalized with incident atrial fibrillation 1995-2008: a Swedish nationwide long-term case-control study, Eur Heart J. 7 avr, vol.34, issue.14, pp.1061-1068, 2013.

E. J. Benjamin, P. A. Wolf, D. Agostino, R. B. Silbershatz, H. Kannel et al., Impact of Atrial Fibrillation on the Risk of Death : The Framingham Heart Study, Circulation. 8 sept, vol.98, issue.10, pp.946-52, 1998.

S. Stewart, C. L. Hart, D. J. Hole, and J. J. Mcmurray, A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study, Am J Med, vol.113, issue.5, pp.359-64, 2002.

P. A. Wolf, R. D. Abbott, and W. B. Kannel, Atrial fibrillation as an independent risk factor for stroke: the Framingham Study, Stroke. 1 août, vol.22, issue.8, pp.983-991, 1991.

A. D. Krahn, J. Manfreda, R. B. Tate, F. Mathewson, and T. E. Cuddy, The natural history of atrial fibrillation: Incidence, risk factors, and prognosis in the manitoba follow-up study, Am J Med. mai, vol.98, issue.5, pp.476-84, 1995.

I. Marzona, M. O'donnell, K. Teo, P. Gao, C. Anderson et al., Increased risk of cognitive and functional decline in patients with atrial fibrillation: results of the ONTARGET and TRANSCEND studies, Can Med Assoc J. 3 avr, vol.184, issue.6, pp.329-365, 2012.

A. Ott, M. Breteler, M. C. De-bruyne, F. Van-harskamp, D. E. Grobbee et al., Atrial Fibrillation and Dementia in a Population-Based Study: The Rotterdam Study, Stroke. 1 févr, vol.28, issue.2, pp.316-337, 1997.

G. Thrall, D. Lane, D. Carroll, and G. Lip, Quality of Life in Patients with Atrial Fibrillation: A Systematic Review, Am J Med. mai, vol.119, issue.5, pp.448-449, 2006.

A. Von-eisenhart-rothe, F. Hutt, J. Baumert, G. Breithardt, A. Goette et al., Depressed mood amplifies heart-related symptoms in persistent and paroxysmal atrial fibrillation patients: a longitudinal analysis-data from the German Competence Network on Atrial Fibrillation, Europace. sept, vol.17, issue.9, pp.1354-62, 2015.

P. Kirchhof, J. Schmalowsky, D. Pittrow, L. Rosin, W. Kirch et al., Management of Patients With Atrial Fibrillation by Primary-Care Physicians in Germany: 1-Year Results of the ATRIUM Registry: Management of AF in clinical practice, Clin Cardiol. mai, vol.37, issue.5, pp.277-84, 2014.

B. A. Steinberg, S. Kim, G. C. Fonarow, L. Thomas, A. J. Kowey et al., Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF), Am Heart J. mai, vol.167, issue.5, pp.735-742, 2014.

J. Davy, F. Roubille, T. Cung, T. Massin, F. Crausac et al., La fibrillation atriale en 2010 : un poids croissant sur la morbidité et la mortalité cardiovasculaires, Ann Cardiol Angéiologie. déc, vol.59, pp.4-13, 2010.
DOI : 10.1016/s0003-3928(10)70002-0

C. Chimenti, M. A. Russo, A. Carpi, and A. Frustaci, Histological substrate of human atrial fibrillation, Biomed Pharmacother. mars, vol.64, issue.3, pp.177-83, 2010.

N. Venteclef, V. Guglielmi, E. Balse, B. Gaborit, A. Cotillard et al., Human epicardial adipose tissue induces fibrosis of the atrial myocardium through the secretion of adipofibrokines, Eur Heart J. 1 avr, vol.36, issue.13, pp.795-805, 2015.

R. G. Hart, L. A. Pearce, and M. I. Aguilar, Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation, Ann Intern Med. 19 juin, vol.146, issue.12, p.857, 2007.
DOI : 10.7326/0003-4819-146-12-200706190-00007

C. T. Ruff, R. P. Giugliano, E. Braunwald, E. B. Hoffman, N. Deenadayalu et al., Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials, The Lancet. mars, vol.383, issue.9921, pp.955-62, 2014.
URL : https://hal.archives-ouvertes.fr/hal-00935589

P. Kirchhof, G. Breithardt, A. J. Camm, H. J. Crijns, K. Kuck et al., Improving outcomes in patients with atrial fibrillation: Rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial, Am Heart J. sept, vol.166, issue.3, pp.442-450, 2013.

A. Sm, A. Lapointe, N. M. Chatterjee, R. Crowley, M. J. Dupre et al., Rateand Rhythm-Control Therapies in Patients With Atrial Fibrillation: A Systematic Review, Ann Intern Med. 3 juin, vol.160, issue.11, p.760, 2014.

R. G. Hart, L. A. Pearce, and M. I. Aguilar, Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation, Ann Intern Med, vol.16, issue.8, pp.590-592, 2007.

. Vidal-previscan, 20 mg cp quadriséc-Pharmacodynamie

. Disponible,

S. J. Connolly, M. D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren et al., Dabigatran versus Warfarin in Patients with Atrial Fibrillation, N Engl J Med. 17 sept, vol.361, issue.12, pp.1139-51, 2009.

M. R. Patel, K. W. Mahaffey, J. Garg, G. Pan, D. E. Singer et al., Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation, N Engl J Med. 8 sept, vol.365, issue.10, pp.883-91, 2011.
URL : https://hal.archives-ouvertes.fr/hal-01038111

C. B. Granger, J. H. Alexander, J. Mcmurray, R. D. Lopes, E. M. Hylek et al., Apixaban versus Warfarin in Patients with Atrial Fibrillation, N Engl J Med. 15 sept, vol.365, issue.11, pp.981-92, 2011.

X. Delavenne, Améliorations pharmacologiques apportées par les nouveaux anticoagulants oraux, Presse Médicale. sept, vol.42, issue.9, pp.1206-1218, 2013.
DOI : 10.1016/j.lpm.2013.06.008

G. Lip, A. Keshishian, S. Kamble, X. Pan, L. Burns et al., A 1:1 PROPENSITYSCORE MATCHED ANALYSIS, J Am Coll Cardiol. avril, vol.67, issue.13_S, pp.882-882, 2016.

S. Halvorsen, W. Ghanima, I. F. Tvete, C. Hoxmark, P. Falck et al., A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants, Eur Heart J-Cardiovasc Pharmacother. 23 sept, p.31, 2016.

X. Yao, N. S. Abraham, L. R. Sangaralingham, M. F. Bellolio, R. D. Mcbane et al., Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation, J Am Heart Assoc. juin, vol.5, issue.6, p.3725, 2016.

K. Senoo and G. Lip, Comparative Efficacy and Safety of the Non-Vitamin K Antagonist Oral Anticoagulants for Patients with Nonvalvular Atrial Fibrillation, Semin Thromb Hemost. 15 févr, vol.41, issue.02, pp.146-53, 2015.

R. P. Giugliano, C. T. Ruff, E. Braunwald, S. A. Murphy, S. D. Wiviott et al., Edoxaban versus Warfarin in Patients with Atrial Fibrillation, N Engl J Med, vol.369, issue.22, pp.2093-104, 2013.
URL : https://hal.archives-ouvertes.fr/hal-00934699

W. H. Organization, Adherence to Long-term Therapies: Evidence for Action. World Health Organization, vol.230, 2003.

P. M. Ho, C. L. Bryson, and J. S. Rumsfeld, Medication Adherence: Its Importance in Cardiovascular Outcomes, Circulation. 16 juin, vol.119, issue.23, pp.3028-3063, 2009.

X. Yao, N. S. Abraham, G. C. Alexander, W. Crown, V. M. Montori et al., Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation, J Am Heart Assoc. févr, vol.5, issue.2, p.3074, 2016.

M. A. Ababneh, A. , S. I. Alzoubi, K. H. Rababa'h, and A. M. , Adherence in outpatients taking warfarin and its effect on anticoagulation control in Jordan, Int J Clin Pharm. août, vol.38, issue.4, pp.816-837, 2016.

J. P. Broderick, J. B. Bonomo, B. M. Kissela, J. C. Khoury, C. J. Moomaw et al., Withdrawal of Antithrombotic Agents and Its Impact on Ischemic Stroke Occurrence, Stroke. 1 sept, vol.42, issue.9, pp.2509-2523, 2011.

S. E. Kimmel, The Influence of Patient Adherence on Anticoagulation Control With Warfarin: Results From the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study, Arch Intern Med. 12 févr, vol.167, issue.3, p.229, 2007.

L. Osterberg and T. Blaschke, Adherence to Medication, N Engl J Med. 4 août, vol.353, issue.5, pp.487-97, 2005.

G. Sanfélix-gimeno, C. L. Rodríguez-bernal, I. Hurtado, C. Baixáuli-pérez, J. Librero et al., Adherence to oral anticoagulants in patients with atrial fibrillation-a population-based retrospective cohort study linking health information systems in the Valencia region, Spain: a study protocol, BMJ Open. 10 janv, vol.5, issue.10, p.7613, 2015.

T. M. Brown, K. Siu, D. Walker, M. Pladevall-vila, S. Sander et al., Development of a Conceptual Model of Adherence to Oral Anticoagulants to Reduce Risk of Stroke in Patients with Atrial Fibrillation, J Manag Care Pharm. juin, vol.18, issue.5, pp.351-62, 2012.

J. B. Olesen, R. Sorensen, M. L. Hansen, M. Lamberts, P. Weeke et al., Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naive atrial fibrillation patients: Danish nationwide descriptive data, Europace. 1 févr, vol.17, issue.2, pp.187-93, 2011.

C. A. Mchorney, C. Crivera, F. Laliberté, W. W. Nelson, G. Germain et al., Adherence to non-vitamin-K-antagonist oral anticoagulant medications based on the Pharmacy Quality Alliance measure, Curr Med Res Opin. déc, vol.31, issue.12, pp.2167-73, 2015.

R. Shameem and J. Ansell, Disadvantages of VKA and requirements for novel anticoagulants, Best Pract Res Clin Haematol. juin, vol.26, issue.2, pp.103-117, 2013.

S. V. Emren, O. ?enöz, M. Bilgin, O. Beton, A. Aslan et al., Drug Adherence in Patients With Nonvalvular Atrial Fibrillation Taking Non-Vitamin K Antagonist Oral Anticoagulants in Turkey: NOAC-TR, Clin Appl Thromb. janv, p.107602961769394, 2017.

L. S. Pfeilschifter, C. Hohmann, D. Niemann, P. Kraft, and I. Gunreben, Adherence to oral anticoagulant therapy in secondary stroke prevention – impact of the novel oral anticoagulants. Patient Prefer Adherence, p.1695, 2015.

A. A. Polymeris, C. Traenka, L. Hert, D. J. Seiffge, N. Peters et al., Frequency and Determinants of Adherence to Oral Anticoagulants in Stroke Patients with Atrial Fibrillation in Clinical Practice, Eur Neurol, vol.76, issue.3-4, pp.187-93, 2016.

J. D. Brown, A. R. Shewale, and J. C. Talbert, Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, Treatment-Naïve Nonvalvular Atrial Fibrillation, J Manag Care Spec Pharm, vol.22, issue.11, pp.1319-1348, 2016.

R. Billé, Agir mais ne rien changer ? De l'utilisation des expériences pilotes en gestion de l'environnement. VertigO, 2009.

. Disponible,

T. F. , Education thérapeutique du patient en médecine générale (représentations, pratiques et attentes des praticiens de la Somme), 2008.

, HAS, commission de transparence. GUIDE PARCOURS DE SOINS-Fibrillation atriale, 2014.

M. Laurens, La perception des médecins généralistes par rapport à l'utilisation des AOD (anticoagulants oraux directs): enquête qualitative en Charente, 2016.

P. Di-borgo and J. , Les nouveaux anticoagulants oraux: entre révolution thérapeutique et vigilance, 2012.

M. ;. Carrier, Évaluation des pratiques des médecins généralistes sur la prescription des anticoagulants oraux directs (dabigatran pradaxa®, rivaroxaban xarelto® et apixaban eliquis®) chez les personnes âgées de plus de 75 ans sur le secteur sanitaire palois, 2014.

M. Vasseur-thelu, Les nouveaux anticoagulants oraux (NACO) (Dabigatran, rivaroxaban): ressenti des médecins généralistes picards sur leurs utilisations et leurs perspectives, 2013.

P. Pinaud, Etude sur la prescription des nouveaux anticoagulants oraux chez les médecins généralistes picards, 2013.

R. ;. Rahmani and . France, Prescription des anticoagulants oraux en médecine générale: étude de pratiques comparant la gestion des anticoagulants oraux directs et des antivitamines k par des médecins généralistes girondins, 2014.

C. Krieger, B. Aleil, and D. Stephan, Les prescripteurs face aux nouveaux anticoagulants oraux, J Mal Vasc, vol.38, issue.5, pp.320-321, 2013.

E. Zucchini, Les nouveaux anticoagulants oraux vus par les médecins généralistes, 2013.

Q. Michel, Perception de l'utilisation des anticoagulants oraux directs: enquêtes auprès des médecins généralistes, 2012.

A. Oulerich, A. Proux, J. Hermil, R. Varin, and J. Doucet, Utilisation des anticoagulants oraux en médecine générale en Haute, 2015.

C. Leblanc and P. Pottier, Ressenti des médecins généralistes sur les anticoagulants oraux directs: enquête qualitative auprès de neuf médecins en Loire Atlantique, 2015.

S. Roy, Ressenti des médecins généralistes face aux anticoagulants oraux directs, 2012.

F. Méar and L. Barreau, Les nouveaux anticoagulants oraux en médecine générale: modalités de prescription et perception par les généralistes. France, 2014.

J. Fabre, L. Breton, and J. , Identification des facteurs associés à la prescription d'un anticoagulant oral direct en médecine générale, vol.80, 2015.

D. E. Morisky, A. Ang, M. Krousel-wood, and H. J. Ward, Predictive Validity of a Medication Adherence Measure in an Outpatient Setting, J Clin Hypertens. mai, vol.10, issue.5, pp.348-54, 2008.

V. Korb-savoldelli, F. Gillaizeau, J. Pouchot, E. Lenain, N. Postel-vinay et al., Validation of a French Version of the 8-Item Morisky Medication Adherence Scale in Hypertensive Adults, J Clin Hypertens. juillet, vol.14, issue.7, pp.429-463, 2012.

Y. Wang, M. C. Kong, and Y. Ko, Psychometric properties of the 8-item Morisky Medication Adherence Scale in patients taking warfarin, Thromb Haemost, vol.108, issue.4, pp.789-95, 2012.

Y. Wang, M. C. Kong, and Y. Ko, Comparison of three medication adherence measures in patients taking warfarin, J Thromb Thrombolysis, vol.36, issue.4, pp.416-437, 2013.

S. J. Cano, D. L. Lamping, L. Bamber, and S. Smith, The Anti-Clot Treatment Scale (ACTS) in clinical trials: cross-cultural validation in venous thromboembolism patients, Health Qual Life Outcomes, vol.10, issue.1, p.120, 2012.

O. Hanon, E. Chaussade, P. Gueranger, E. Gruson, S. Bonan et al., Patient-Reported Treatment Satisfaction with Rivaroxaban for Stroke Prevention in Atrial Fibrillation. A French Observational Study, the SAFARI Study. Pizzi C, éditeur, PLOS ONE. 9 déc, vol.11, issue.12, p.166218, 2016.

G. Lip, R. Nieuwlaat, R. Pisters, D. A. Lane, and H. Crijns, Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach, Chest. févr, vol.137, issue.2, pp.263-72, 2010.

R. Pisters, D. A. Lane, R. Nieuwlaat, C. B. De-vos, H. Crijns et al., A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation. Chest, vol.138, pp.1093-100, 2010.

R. Mehran, S. V. Rao, D. L. Bhatt, C. M. Gibson, A. Caixeta et al., Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium, Circulation. 14 juin, vol.123, issue.23, pp.2736-2783, 2011.

M. Almegren, Reversal of direct oral anticoagulants. Vasc Health Risk Manag, vol.13, pp.287-92, 2017.

S. Hussain, S. , H. Tyroch, A. Mukherjee, and D. , Reversal of Newer Direct Oral Anticoagulant Drugs (DOACs), Cardiovasc Hematol Agents Med Chem. 18 janv, vol.14, issue.2, pp.76-81, 2017.

A. Gomez-outes, M. L. Suarez-gea, R. Lecumberri, A. I. Terleira-fernandez, and E. Vargas-castrillon, Specific antidotes in development for reversal of novel anticoagulants: a review. Recent Patents Cardiovasc Drug Discov, vol.9, pp.2-10, 2014.

R. Tummala, A. Kavtaradze, A. Gupta, and R. K. Ghosh, Specific antidotes against direct oral anticoagulants: A comprehensive review of clinical trials data, Int J Cardiol. juill, vol.214, pp.292-300, 2016.

A. J. Singer, A. Quinn, N. Dasgupta, and T. Hc, Management and Outcomes of Bleeding Events in Patients in the Emergency Department Taking Warfarin or a Non-Vitamin K Antagonist Oral Anticoagulant, J Emerg Med, p.17, 2016.

. Disponible,

L. Staerk, E. L. Fosbøl, G. Lip, M. Lamberts, A. N. Bonde et al., Ischaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide cohort study, Eur Heart J, p.496, 2016.

P. Sardar, S. Chatterjee, S. Chaudhari, and G. Lip, New Oral Anticoagulants in Elderly Adults: Evidence from a Meta-Analysis of Randomized Trials, J Am Geriatr Soc. mai, vol.62, issue.5, pp.857-64, 2014.

P. Sardar, S. Chatterjee, E. Herzog, R. Nairooz, D. Mukherjee et al., Novel Oral Anticoagulants in Patients With Renal Insufficiency: A Meta-analysis of Randomized Trials, Can J Cardiol. août, vol.30, issue.8, pp.888-97, 2014.

L. Bamber, M. Y. Wang, M. H. Prins, C. Ciniglio, R. Bauersachs et al., Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis, Thromb Haemost. 11 juill, vol.110, issue.4, pp.732-773, 2013.

R. Sørensen, J. Nielsen, B. , L. Pallisgaard, J. et al., Adherence with oral anticoagulation in non-valvular atrial fibrillation: a comparison of vitamin K antagonists and non-vitamin K antagonists, Eur Heart J-Cardiovasc Pharmacother. juill, vol.3, issue.3, pp.151-157, 2017.

G. De-pouvourville, Anticoagulants d'action directe: une revue de la littérature des études coût/efficacité en Europe, Arch Cardiovasc Dis Suppl. février, vol.8, issue.2, pp.180-91, 2016.

L. France,

, Enquête nationale : effectifs étudiants, enseignants, nombre de stage en médecine générale, 2014.

. Hautes-alpes, des arrivées toujours plus nombreuses-Insee Analyses, 2017.

R. T. Borne, C. O'donnell, M. P. Turakhia, P. D. Varosy, C. A. Jackevicius et al., Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration, BMC Cardiovasc Disord, vol.17, issue.1, p.11, 2017.

J. M. Rivera-caravaca, M. A. Esteve-pastor, V. Roldán, F. Marín, and G. Lip, Non-vitamin K antagonist oral anticoagulants: impact of non-adherence and discontinuation, Expert Opin Drug Saf. 2 sept, vol.16, issue.9, pp.1051-62, 2017.

M. H. Kim, S. S. Johnston, B. Chu, M. R. Dalal, and K. L. Schulman, Estimation of Total Incremental Health Care Costs in Patients With Atrial Fibrillation in the United States, Circ Cardiovasc Qual Outcomes. 1 mai, vol.4, issue.3, pp.313-333, 2011.

L. A. Castellucci, J. Shaw, . Salm-k-van-der, P. Erkens, G. L. Gal et al., Self-reported adherence to anticoagulation and its determinants using the Morisky medication adherence scale, Thromb Res, vol.136, issue.4, pp.727-758, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01259485

S. I. Patel, C. Cherington, R. Scherber, K. Barr, R. Mclemore et al., Assessment of Patient Adherence to Direct Oral Anticoagulant vs Warfarin Therapy, J Am Osteopath Assoc. 1 janv, vol.117, issue.1, p.7, 2017.

G. Maura, A. Pariente, A. F. Billionnet, and C. , Adherence with direct oral anticoagulants in nonvalvular atrial fibrillation new users and associated factors: a French nationwide cohort study, Pharmacoepidemiol Drug Saf, p.11, 2017.

. Disponible,

A. Y. Mayet, Patient adherence to warfarin therapy and its impact on anticoagulation control, Saudi Pharm J SPJ. janv, vol.24, issue.1, pp.29-34, 2016.
DOI : 10.1016/j.jsps.2015.02.005

URL : https://doi.org/10.1016/j.jsps.2015.02.005

J. Schneider, S. H. Kaplan, S. Greenfield, W. Li, and I. B. Wilson, Better physician-patient relationships are associated with higher reported adherence to antiretroviral therapy in patients with HIV infection, J Gen Intern Med. nov, vol.19, issue.11, pp.1096-103, 2004.

M. R. Dimatteo, C. D. Sherbourne, R. D. Hays, L. Ordway, R. L. Kravitz et al., Physicians' characteristics influence patients' adherence to medical treatment: Results from the Medical Outcomes Study, Health Psychol, vol.12, issue.2, pp.93-102, 1993.

E. H. Lin, V. Korff, M. Katon, W. Bush, T. Simon et al., The role of the primary care physician in patients' adherence to antidepressant therapy, Med Care. janv, vol.33, issue.1, pp.67-74, 1995.

F. Pan, M. E. Chernew, and A. M. Fendrick, Impact of Fixed-Dose Combination Drugs on Adherence to Prescription Medications, J Gen Intern Med. mai, vol.23, issue.5, pp.611-615, 2008.

C. A. Mchorney, E. D. Peterson, F. Laliberté, G. Germain, W. W. Nelson et al., Comparison of Adherence to Rivaroxaban Versus Apixaban Among Patients With Atrial Fibrillation, Clin Ther, vol.38, issue.11, pp.2477-88, 2016.

F. Laliberté, B. K. Bookhart, W. W. Nelson, P. Lefebvre, J. R. Schein et al., Impact of Once-Daily Versus Twice-Daily Dosing Frequency on Adherence to Chronic Medications among Patients with Venous Thromboembolism, Patient-Patient-Centered Outcomes Res. sept, vol.6, issue.3, pp.213-237, 2013.

F. Laliberté, W. W. Nelson, P. Lefebvre, J. R. Schein, J. Rondeau-leclaire et al., Impact of Daily Dosing Frequency on Adherence to Chronic Medications Among Nonvalvular Atrial Fibrillation Patients, Adv Ther. août, vol.29, issue.8, pp.675-90, 2012.

M. W. Sherwood, J. D. Douketis, M. R. Patel, J. P. Piccini, A. S. Hellkamp et al., Outcomes of Temporary Interruption of Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation: Results From the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF), Circulation. 6 mai, vol.129, issue.18, pp.1850-1859, 2014.

, Fibrillation auriculaire non valvulaire, quelle place pour les anticoagulants oraux?, Juillet, 2013.

X. Tan, I. Patel, and J. Chang, Review of the four item Morisky Medication Adherence Scale (MMAS4) and eight item Morisky Medication Adherence Scale (MMAS-8), Innov Pharm [Internet]. 1 janv, vol.5, issue.3, 2014.

C. Etude, , p.12, 2017.

D. Kirchhof, P. Benussi, S. Kotecha, D. Ahlsson, A. Atar et al., ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS, Eur Heart J, vol.37, issue.38, pp.2893-962, 2016.

, Sauf en cas de refus de votre part, vous serez destinataire des résultats de cette recherche. Les questionnaires sont à renvoyer par Fax ou courrier

, Cette étude a été approuvée au préalable par un comité de protection des personnes. Cordialement. Paul LEMIERE Coordonnées : 06.22.92.31.66 ; paul.lemiere@yahoo.fr Adresse de renvoi : CHICAS Gap service de cardiologie 1

D. Camm, A. J. Kirchhof, P. Lip, and G. , Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC), Eur Heart J, vol.31, pp.2369-429, 2010.

D. Morisky, D. E. Ang, A. Krousel-wood, M. Ward, and H. J. , Predictive Validity of a Medication Adherence Measure in an Outpatient Setting, J Clin Hypertens, vol.10, issue.5, pp.348-54, 2008.

, Stratégies d'amélioration de l'adhérence à un traitement

D. Osterberg, L. Blaschke, and T. , Adherence to Medication, N Engl J Med. 4 août, vol.353, issue.5, pp.487-97, 2005.